Abstract | Uric acid is a waste product of purine catabolism. This molecule comes to clinical attention when it nucleates to form crystals of monosodium urate (MSU) in joints or other tissues, and thereby causes the inflammatory disease of gout. Patients with gout frequently suffer from a number of comorbid conditions including hypertension, diabetes mellitus and cardiovascular disease. Why MSU crystals trigger inflammation and are associated with comorbidities of gout has been unclear, but recent studies provide new insights into these issues. Rather than simply being a waste product, uric acid could serve a pathophysiological role as a local alarm signal that alerts the immune system to cell injury and helps to trigger both innate and adaptive immune responses. The inflammatory component of these immune responses is caused when urate crystals trigger both inflammasome-dependent and independent pathways to generate the proinflammatory cytokine IL-1. The resulting bioactive IL-1 stimulates the inflammation of gout and might contribute to the development of other comorbidities. Surprisingly, the same mechanisms underlie the inflammatory response to a number of irritant particles, many of which also cause disease. These new insights help to explain the pathogenesis of gout and point to potential new therapeutic targets for this and other sterile inflammatory diseases.
Introduction
Gout is a prevalent disease, affecting 8.3 million adults in the USA in [2007] [2008] . 1 The disease manifests most commonly as episodes of acute and extremely painful arthritis, classically affecting the big toe, but in some cases involving other joints as well. 2 In addition, hard nodules called tophi can develop in a range of locations (such as the helix of the ear, the olecranon process of the elbow and the Achilles tendons of the foot) and, in some patients, deposits in the kidney cause renal damage, which is the most serious complication of the disease. Gout is triggered when crystals of monosodium urate (MSU)-a crystallized form of uric acid-nucleate in joints, kidneys and other tissues, where they incite inflam mation. Patients with gout frequently have other comor bidities, including renal disease, metabolic sy ndrome, diabetes mellitus and hypertension. 3 Although it has long been known that uric acid causes gout, many unresolved questions persisted. Why is the crystallized form of uric acid so inflammatory? How do these crystals actually trigger inflammation; that is, which cells, molecular sensors and mediators drive this response? What is the relationship, if any, of inflammation to uric acid, and of inflammation to other pro inflammatory particles and sterile inflammatory diseases? How are comorbidities of gout related to uric acid? This article reviews recent advances in the field, with an emphasis on research since 2000, that are begin ning to shed light on many of these issues. We discuss how uric acid is produced and what is known about its functions, with a focus on its role as an immunological danger signal. We explore new insights into how uric acid crystals stimulate inflammation and how these mecha nisms are unexpectedly shared in the inflammation and diseases caused by many other, unrelated, irritant parti cles. Finally, we discuss the therapeutic implications of these insights into the underlying mechanisms of gout.
Physiology of uric acid
Uric acid is generated as part of the normal turnover of nucleic acids ( Figure 1 ). This molecule is produced when purines, for example from DNA or RNA, are oxidized by xanthine oxidase, an enzyme present in the peroxisomes of most cells. This process occurs continuously and, con sequently, uric acid is present as a normal constituent intracellularly and in biological fluids. In healthy indivi duals, uric acid is present in the blood at concentrations of ~6.0 mg/dl, which is a remarkably high level given that the threshold for saturation of this molecule in biological fluids is ~7.0 mg/dl. 4 When individuals develop hyper uricaemia as a consequence of excessive intake of purines and/or genetic predisposition, uric acid saturates body fluids, and these individuals are then at risk of MSU crys tals nucleating in their joints and elsewhere. As further discussed below, it is these crystals that trigger symptoms and cause disease.
Most mammals express in their livers uricase, a peroxi somal enzyme that oxidizes uric acid to allantoin, which is highly soluble, and water. 5 This endogenous uricase lowers uric acid levels somewhat and consequently these of uric acid might be expected to be evident in indivi duals lacking uric acid; however, patients with the genetic condition xanthinuria-a deficiency of xanthine oxidase -completely lack uric acid, yet are not known to suffer any untoward consequences other than the development of xanthine stones. 7 Therefore, high levels of uric acid do not seem to be essential in normal physiological condi tions. With that being said, this finding does not rule out the possibility that uric acid has a physiological role in more selective situations and there are hints that this might be the case. High levels of uric acid are associ ated with protection against a number of neurological diseases including multiple sclerosis, Parkinson disease, Alzheimer disease and amyotrophic lateral sclerosis; [8] [9] [10] [11] however, whether this protection is attributable to uric acid's antioxidant activity or to other of its properties is not known. As discussed next, recent studies point to a different potential pathophysiological role for uric acid, in alerting the immune system to danger.
Uric acid as a danger signal
Cell damage and necrosis is potentially dangerous to an organism; it is the manifestation of some underlying pathological process or agent that is injuring cells. As such, it is in the interest of the host to try to limit and repair such damage. If the injurious agent is a microbe, the immune system has a number of molecular sensors, such as Tolllike receptors (TLRs), NODlike receptors (NLRs) and RIGlike receptors (RLRs), to detect and respond to pathogens. 12 The 'danger hypothesis' (Box 1) additionally proposes that the immune system has also evolved mechanisms to monitor the health of cells, 13 a concept that is now accepted as correct. The innate immune system performs this monitoring function by surveying the extracellular environment for the presence of a subset of molecules that are normally sequestered in the interior of cells, but that are exposed upon loss of integrity of the plasma membrane.
14 Rupture of the cell membrane is an invariable consequence of necro sis. Therefore, by monitoring the environment for the release of intracellular molecules, the immune system can detect and respond to injurious processes that pose a danger to the host, and thereby attempt to limit and repair any damage. The intracellular molecules whose release signals danger are referred to as danger signals or damageassociated molecular patterns (DAMPs).
14 Uric acid, it turns out, is one of these DAMPs. 4 Danger, adaptive immunity and uric acid To protect us against disease, the immune system con tinu ously monitors our tissues for the presence of antigens. To accomplish this important task, dendritic cells (DCs) are deployed in the tissues, where they collect antigens and display them as peptides bound to MHC class I and class II molecules (Box 2). 15 These cells subsequently migrate to draining lymph nodes where they report their findings to T cells. 15 T cells with the appropriate specificity will recognize the presented antigen. However, whilst recog nition of antigens bound to MHC molecules is necessary, it is not sufficient to initiate a Tcell immune response. Figure 1 | Biochemistry of uric acid and its homeostasis. Purines are absorbed from the diet through the gut, synthesized in the body and/or derived from the degradation of endogenous DNA and RNA. They are further oxidized by xanthine oxidase. Uric acid is the major end product of purine metabolism in humans. The majority of uric acid is excreted by the kidney and the rest in feces, although a substantial amount of uric acid is reabsorbed at the proximal tubule of the kidney. This is because T cells must also receive other activation signals from DCs, 16 and these costimulatory signals are not present under basal conditions. Instead, DCs must be stimulated in ways that cause them to express costimu latory signals (Figure 2 ). In order for this expression to occur, the DCs must be exposed to microbial signals or DAMPs, which are present in precisely those situations (infections and cell injury) that the immune system needs to investigate. In other words, the requirement for DC activation enables the immune system to focus its attention on antigens that are associated with patho genic processes. The need for DC activation explains why the simple injection of antigens does not usually induce immune responses, and why ad mixing such antigens with adjuvants (most often containing bacterial products) p romotes such responses. [17] [18] [19] Through these mechanisms, dying cells stimulate DC activation and, when injected into animals admixed with antigen, provide an adjuvant function that promotes Tcell and Bcell responses. 20, 21 One of the immune promoting factors isolated from dead cells was identi fied as uric acid. 4 Cells normally contain very high levels of this molecule intracellularly and produce even more upon death as their purines are released and metabo lized. 4, 22 To become immunologically active, it is thought that uric acid has to undergo a phase change to MSU crystals. 4 Pure MSU crystals have been shown to both activate DCs and augment immune responses. 4 These crystals are thought to form around dying cells when intracellular stores of uric acid are released and create a supersaturated solution in the highsodium extra cellular environment, although this mechanism has not been proven. 23 Uric acid is not the only DAMP released from dying cells but it seems to be an important one, as depleting uric acid from dead cells reduces their adju vant activity. 4 Whether different DAMPs-HMGB, S100 proteins, ATP and DNA, to name a few-have different mechanisms of action or biological effects is unclear.
As described above, the release of uric acid and other DAMPs is thought to contribute to host defense. In some circumstances, however, this release might also contri bute to disease, including autoimmune ones of rheuma tological interest. By way of background, autoimmune diseases are thought to require components of both 'nature' and 'nurture' . The genetic component, where allelic variants or mutations predispose an individual to autoimmune disease, is strong. In studies of identi cal twins, however, the concordance rate is only ~25% in many of these diseases; 24 therefore, it is thought that in addition to genetic susceptibility, an environmental trigger is also required. Infection and tissue injury have been implicated as triggers of autoimmunity and these events might act by stimulating DCs to present self antigens in ways that initiate an autoimmune response in susceptible individuals. [25] [26] [27] [28] [29] [30] Innate responses to uric acid and particles It has long been recognized that sites of tissue necrosis become inflamed: 31 vessels vasodilatate, fluid leaks cause oedema, and leukocytes infiltrate the site of injury. The net effect of this process is that the soluble and cellu lar innate immune defenses are delivered to the tissue where cells are dying. This response can help to limit the injurious process and ultimately to promote repair. On the other hand, inflammation causes symptoms (pain, heat and swelling) and can itself cause damage to the tissue. Indeed, inflammation is thought to underlie or contribute to the pathogenesis of a number of medically important diseases, including ones associated with cell death (stroke and other infarcts, tissue damage from toxic agents, and so on). 14 The release of DAMPs by dying cells stimulates tissueresident macrophages to produce proinflamma tory mediators that drive the inflammatory response. 14, 32 The molecular species of DAMPs that trigger these acute responses are not fully known, but include uric acid. 22 As mentioned above, the biologically active form of uric acid is thought to be crystallized MSU that forms when intracellular stores of uric acid are released into the extra cellular environment. As noted earlier, nuclea tion of MSU crystals in other situations, such as in gout, stimulates robust inflammation. Gout could, therefore, be viewed as a disease that is triggered when a normal bioactive mediator is overproduced and generated in appropriately (for example, in a joint).
The phenomenon that irritant particles can be highly proinflammatory is not limited to MSU crystals; indeed, many crystals and particles can stimulate inflamma tion and cause disease, including several diseases of rheumato logical interest (Table 1) . Although these various particles are structurally quite distinct, they stimulate inflammation through similar pathways.
Box 1 | Immunological danger
The immune system was classically thought to have evolved to protect the host against foreign invaders, and does so by first discriminating between autologous (self) molecules and foreign ones, and then responding against the latter.
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However, the presence of a foreign substance does not always trigger an immune response and, conversely, the immune system sometimes reacts to autologous constituents. In considering these issues, Matzinger proposed the idea that the immune system actually evolved to protect the host against antigens that are dangerous or associated with a dangerous situation, regardless of whether or not they are foreign. 13 'Danger' in this context is the potential to cause injury to the host. Thus, it was proposed that the immune system does not discriminate between antigens that are foreign versus self, but rather between ones that are or are not dangerous.
Box 2 | MHC molecules and antigen presentation
The immune system evolved MHC class I and II molecules to monitor various cellular compartments for the presence of antigens (in the form of peptide fragments). MHC class I molecules bind peptides derived from proteins degraded in the cytosol, nucleus and endoplasmic reticulum and then transport them to the cell surface for display. 118 This display enables CD8 + T cells, which express receptors for peptide-MHC class I complexes, to monitor cells and detect those synthesizing foreign antigens; for example, from a viral infection. By contrast, MHC class II molecules bind peptides from proteins degraded in the endocytic compartments of cells. 119 In this way, CD4 + T cells, which have receptors that recognize peptide-MHC class II complexes, can detect foreign antigens (for example, microbes and toxins) from the extracellular milieu that have been internalized into cells that express MHC class II (dendritic cells, macrophages and B cells).
IL-1 in sterile inflammation
Dying cells, MSU crystals and other irritant particles all cause inflammation by stimulating the production of inflammatory cytokines. For all of these stimuli, a key mediator of the inflammatory response is IL1 (Table 1) . 33 This IL1driven inflammation which occurs in the absence of infection, differs from that in some other inflammatory diseases, such as rheumatoid arthri tis, in which TNF has a more dominant role than IL1. 34 However, mice genetically deficient in the IL1 pathway (lacking either the cytokine or its receptor) produce little inflammation in response to injection of dead cells, MSU crystals, silicates, asbestos, alum, cholesterol or other irritant particles. By contrast, celldeathinduced inflam matory responses are only modestly reduced in mice lacking the TNF pathway in comparison with wildtype mice. 35 In vitro, dying cells and irritant particles stimulate both mouse and human macrophages to produce IL1. 36 The IL1 released is a potent stimulator of neutrophilic inflammation and can stimulate other tissue responses, such as fibrosis. 37 Active IL1 exists in two forms, IL1α and IL1β, which are the products of distinct but homologous genes. 38 Both of these forms of IL1 bind to the same receptor, IL1R1. 38 Most work on sterile inflammation has demonstrated a role for IL1β. However, where examined (including in response to MSU crystals), IL1α also contributes to inflammation and does so to a substantial extent.
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Production of IL-1 in sterile inflammation
The production of bioactive IL1β is a multistep pro cess. Cells must first be stimulated in ways that induce transcription of the IL1β gene. 41 TLR agonists (micro bial molecules) and cytokines such as TNF stimulate the transcription of this gene, in part by activating the transcription factor NFκB. 41, 42 What stimulates this step for irritant particles in vivo is a bit of a mystery, because these particles are sufficient to stimulate IL1 responses in vivo, yet in vitro require that the IL1producing cells first be stimulated with microbial molecules or cytokines. In any case, once produced, the IL1β transcript encodes an inactive precursor of the cytokine that, when trans lated, contains an Nterminal prosequence. 41 To become biologically active, another step is required in which the prosequence is removed. 41 Caspase1 is the protease that cleaves proIL1β into mature IL1 β, at least in leuko cytes in vitro; 41 as discussed below, the situation is more complex in vivo.
The activity of caspase1 is tightly regulated. This pro tease is initially made as a zymogen (an inactive precur sor) whose activity is controlled by a macromolecular com plex known as the inflammasome (Figure 3 ). The inflam masome is made up of three components. 43, 44 The first element is an NLR protein, which is thought to impart specificity and control the activity of the com plex. The NLR proteins have leucinerich repeat domains, similar to TLRs, and these are thought to be involved in substrate recognition. The NLR also contains proteininteraction domains that enable it to associate with the second component, the scaffolding protein ASC ( apoptosisassociated specklike protein containing a caspase recruitment domain). ASC associates with the third element of the inflammasome, procaspase1. When assembled, these three components form the inflammas omes, which can in turn form large macro scopic struc tures termed 'specks' . Stimulation of the inflammasome complex leads to the cleavage and activation of caspase1, which in turn cleaves IL1 (Figure 3) .
The NLR protein involved in sterile inflammatory responses to MSU crystals and other irritant particles is NLRP3 (Table 1) . Mutant macrophages that lack this protein are unable to make active IL1 when stimulated with irritant particles including MSU, calcium pyroph osphate, silicates, asbestos, cholesterol crystals and alum. NLRP3 is also of rheumatological interest because rare mutations in this protein lead to overproduction of IL1, which causes the autoinflammatory diseases familial cold autoinflammatory syndrome, Muckle-Wells syn drome and neonatalonset multisystem inflammatory disease. [45] [46] [47] [48] These diseases are characterized by fever, rash and arthritis, among other symptoms.
IL1α is also made with a prosequence; however, in contrast to IL1β, it is biologically active with or without cleavage of its Nterminal prosequence. 41 The cleavage of proIL1α into mature IL1α is not medi ated by caspase1, but by distinct proteases including calpain (a calciumactivated cysteine protease), 49 gran zyme B and possibly elastase and chymase. 50 Although the inflammasome is not involved in the processing of proIL1α, surprisingly, it somehow controls the release of soluble IL1α from cells. [51] [52] [53] Perhaps this control of IL1α release is because the inflammasome is needed to produce mature IL1β, and IL1β has been suggested to bind to IL1α and in so doing facilitate its release from cells. 51 IL1α can also be expressed on the plasma membrane, and the surface expression of this form is not dependent on IL1β.
Stimulation of the NLRP3 inflammasome
The identification of NLRP3 as a sensor for MSU crys tals and other irritant particles initially presented a bit of a puzzle, because this NLR protein seemed to be in the wrong cellular compartment to be able to sense the particles. The NLRP3 inflammasome is an intracellular complex that resides in the cytosol of cells. By contrast, the stimuli discussed above that trigger this complex are large macroscopic particles that, when present in the body, are initially located outside of cells. This obser vation raises the interesting question: how do these extracellular particles trigger the intracellular NLRP3 inflammasome? The first step in the process occurs when phagocytes ingest these particles (Figure 4) . 54, 55 Suppression of phagocytosis by treating macrophages in vitro with cytochalasins or colchicine (inhibitors of actin and tubulin polymerization, 56,57 respectively) blocked urateinduced NLRP3 activation; 54, 58, 59 as an aside, this mechanism might explain in part why colchi cine is an effective therapeutic agent for acute attacks of gout, although this drug also affects other components of the inflammatory response. 60 Once the par ticles are in phagosomes, they can stimulate the NLRP3 inflam masome by way of at least two different mechanisms, one of which involves reactive oxygen species (ROS) and another involves phagosomal proteases (Figure 4) .
In support of a mechanism involving ROS, small molecule scavengers of these reactive species were found to inhibit the ability of irritant particles to stimu late NLRP3 inflammasomes. 61 This finding led to a model proposing that internalized particles stimulate phagocytes to produce ROS, which in turn activate the NLRP3 inflammasomes. 62 This model was appeal ing because ingestion of particles such as bacteria can stimulate NADPH oxidase in phagosomes to produce ROS (known as the oxidative burst); however, the ability of irritant particles to stimulate NLRP3 inflammasomes was not diminished in mouse or human cells genetically lacking NADPH oxidase. 54, 63 Therefore, if this model is correct, then there must be an alternative source of ROS. A study published in 2011 suggested that internalization of irritant particles somehow stimulates mitochon dria to produce ROS, although exactly how this occurs is not yet clear. 64 It is also not entirely clear how ROS lead to inflammasome activation. Limited data shows that ROS alter the redox potential in cells in ways that lead to the release from thioredoxin of thioredoxin interacting protein (TXNIP), a putative endogenous ligand for NLRP3 (Figure 4) . 62 However, cells from TXNIPdeficient mice did not show reduced production of IL1β in response to MSU crystals or other particles; 65 therefore, the importance of this mechanism is unclear.
A second mechanism by which particles might stimu late NLRP3 inflammasomes in cells involves lysosomal proteases ( Figure 4) . 54, 55 When macrophages ingest particles, their phagosomes are subsequently acidi fied, which in turn activates acidoptimal proteases to digest the phagosomal contents. This process is part of the normal physiology by which phagocytes digest what they have ingested. Blocking vesicular acidification has been shown to inhibit the ability of irritant particles to stimulate NLRP3 inflammasomes, as was inactivation of certain cathepsins (cathepsin B and cathepsin L) with inhibitors or genetic mutations, in many 54, [66] [67] [68] but not all studies. 69, 70 Furthermore, particlecontaining phago somes have been found to leak their contents into the cytosol, 54, 71 and such vesicular leakage, even when not resulting from treating macrophages with particles (for example, caused by osmotic rupture), was shown to be sufficient to stimulate NLRP3 inflammasomes. 54 On the basis of these findings, it has been hypothesized that NLRP3 does not directly sense particles, but rather senses the internal cell damage that they cause-the rupture or leakage of lysosomes or phagosomes. How does NLRP3 sense this event? Although the answer is not yet clear, it has been hypothesized that activated cathep sins stimulate NLRP3 by cleaving it into an active state or by generating a stimulatory ligand for this NLR.
Other mechanisms might also contribute to the activa tion of NLRP3. For example, some evidence exists that potassium efflux can be triggered by known NLRP3 acti vators and that this efflux somehow promotes NLRP3 inflammasome activation. [72] [73] [74] In addition, oxidized DNA released from damaged mitochondria can directly bind to and activate the NLRP3 inflammasome. 75 A number of different mechanisms for activating NLRP3 could be interconnected. For example, it turns out that a number of NLRP3 activators (such as alum, ATP and nigericin), potassium efflux and lysosomal damage can all lead to mitochondrial dysfunction and release of oxidized DNA. 75 Moreover, inhibition of potassium efflux rescued mitochondrial dysfunction following treatment of macrophages with NLRP3 activators (including ATP, nigericin, staurosporine, and infection by Chlamydia pneumoniae), and thereby reduced IL1β secretion by these cells. 75 
Inflammasome-independent pathways
The production of bioactive IL1β by cells in culture is absolutely dependent on the inflammasome. Con sequently, macrophages genetically lacking any of the inflammasome components fail to produce any mature IL1β after stimulation with MSU crystals or other irri tant particles in vitro. By contrast, IL1βdependent inflammation in vivo is often only modestly reduced in animals genetically lacking the same inflamma some components (K. L. Rock, unpublished data). 76, 77 These results indicate that additional mechanisms must be operative in vivo that can cleave proIL1β into mature IL1β.
Indeed, in addition to caspase1, a number of other proteases, including neutrophil serine proteases (elastase, cathepsin G and protease 3), mast cell chymase, and matrix metalloproteinases, can cleave purified proIL1β into bioactive IL1β, at least in the test tube. 41, [78] [79] [80] [81] Many of these proteases are serine proteases that are present in vacuoles of leukocytes, including neutrophils, macro phages and mast cells. Most of these IL1cleaving pro teases are themselves produced as zymogens and require removal of a prosequence to become active. This acti vating cleavage is performed by a single vacuolar pro tease, cathepsin C. 82, 83 Mice that lack cathepsin C (and hence the IL1cleaving serine proteases) produce less bioactive IL1β and generate attenuated inflammation in response to injection with anticollagen antibodies, zymosan, immune complexes, 84 and irritant particles (K. L. Rock, unpublished data), although responses to MSU crystals were not examined. On the other hand, these mutant animals generate normal inflamma tory responses when injected with recombinant IL1β (K. L. Rock, unpublished data). These results indicate that cathepsin Cdeficient mice are fully capable of responding to IL1β, but when injected with particles, the mice do not seem to produce enough of this cytokine to drive inflammation. Mice lacking both cathepsin C and an inflammasome component (caspase1) show an additive defect in bioactive IL1β production and inflam mation to irritant particles (K. L. Rock, unpublished data). These results in mice implicate cathepsin C in the inflammasomeindependent pathway of IL1β process ing in vivo, presumably through the role of cathepsin C in activating serine proteases capable of cleaving IL1β. Consistent with these findings, chemical inhibitors of some of these serine proteases similarly inhibit IL1β production in models of inflammatory arthritis and MSU crystalinduced inflammation in vivo. 76, 77 At exactly what stage the inflammasomeindependent proteases cleave IL1 is not known. It is unclear whether they process proIL1 β to mature IL1β in cells prior to the release of the cytokine (and if so, where this occurs in cells) and/or they cleave proIL1β in the extracellular space after it is released from living or dying cells. The secretion of IL1α by cultured macrophages stimulated with MSU crystals seems to be only par tially dependent on inflammasomes. 40 Possibly, this IL1α secretion also contributes to IL1dependent, inflammasomeindependent responses in vivo.
Other effects of uric acid and particles
Other than the inflammasomedependent and inflam masomeindependent mechanisms discussed above, MSU stimulates cells by way of other pathways. TLR2 signaling has been shown to be essential for chondro cyte production of nitric oxide induced by MSU or calcium pyrophosphate dihydrate, 85 and to augment inflammasomedependent responses. 86 However, TLR2 is not required for responses to such stimuli in all situa tions. For example, in other settings, MSU still acti vated antigenpresenting cells with doubledeficiency of MyD88 and Trif (the adaptor proteins required for signalling through all TLRs), 87 and in mice deficient for TLR2, the inflammation induced by MSU was not reduced in comparison to wildtype mice. 36 MSU can also bind CD14 on macrophages to enhance expression and processing of IL1β and CXCL1 expression through p38 activation. 88 Direct binding of MSU to the plasma membrane can even lead to aggregation of the lipid rafts to induce Syk-phosphatidylinositol 3kinase activation in DCs without the requirement of specific receptors on the plasma membrane. 87 Protein kinase C has been implicated in MSUstimulated neutrophil degranulation and migration. 89 MSU might also activate the comple ment pathway to induce inflammatory response. 56, 90 Phago cytosis of MSU activates cyclooxygenase 2 expres sion and prostaglandin E 2 (PGE 2 ) production in human peripheral blood mononuclear cells, and treat ment with colchicine has been shown to block these effects. 91 Particulates, including alum, silica and nickel oxide, have also been shown to stimulate PGE 2 produc tion through an inflammasomeindependent pathway. 92 Upon phagocytosis, these particulates cause lysosomal disruption that leads to Syk-p38 mitogenactivated protein kinase-cytosolic phospholipase A 2 activation and subsequent production of PGE 2.
92 Interestingly, the induced PGE 2 mediates the adjuvanticity of alum and nickel oxide in antigenspecific IgE response. 
Uric acid and comorbidities of gout
Patients with gout frequently have a number of comor bid conditions, which can include renal dis ease, hyper tension, diabetes mellitus, metabolic syndrome, cardio vascular disease, lipid disorders and respiratory symp toms. 3, 93, 94 Some of these comorbidities, such as renal disease, can contribute to the pathogenesis of gout by elevating serum levels of uric acid; in other words, some comorbidities may be a cause rather than an effect of elevated levels of uric acid. In other cases, how ever, the possibility has been raised that high uric acid levels or gout, or both, might contribute to the development of comor bidities, possibly including hypertension, meta bolic syndrome and atherosclerosis. Determining cause and effect of gout and its comorbidities, and elucidating the mechanisms underlying these epidemiological asso ciations, is not trivial and, at this point, is unresolved. Some of these associations are briefly reviewed below, and interested readers are referred to more indepth reviews published elsewhere. 3, 93, 94 Epidemiologic studies have found an association between high levels of uric acid and hypertension, and multivariate analyses have suggested that hyper uricaemia is an independent risk factor for this comorbidity. 3, 93, 94 Interestingly, experimentally elevating levels of uric acid in animals raises blood pressure and this effect can be reversed by inhibiting uric acid synthesis. 3, 93, 94 Consistent with these findings, pharmacological lowering of uric acid levels reduced blood pressure in a small study of normal human subjects. 3, 93, 94 The limited data from these studies suggest that high serum levels of uric acid might somehow cause hypertension.
Similarly, human epidemiological data show associa tions between atherosclerosis and cardiovascular disease and gout and/or hyperuricaemia. 3, 93, 94 In some but not all studies, gout or hyperuricaemia, or both, have been independent risk factors for such disease. 3, 93, 94 Limited data show that hyperuricaemia is associated with vas cular endothelial dysfunction in rats, [95] [96] [97] and that lowering uric acid levels in humans may improve vas cular flow. 98 In vitro studies suggest that hyper uricaemia causes calcium ion overload in mitochondria to produce excess ROS, which cause endothelial dysfunction. 99 The increased ROS, at least in part, reduce endothelial pro duction of nitric oxide and the expression of endothelial nitric oxide synthase. 100, 101 Some human epidemio logical data also shows a higher incidence of metabolic syndrome and insulin resistance in patients with gout as compared with the general population. 3, 93, 94 Interestingly, in a model of metabolic syndrome in fructosefed rats, pharmaco logical lowering of uric acid levels resulted in increased insulin sensitivity. 102 However, cause and effect are not firmly established in any of these comorbidities.
If uric acid contributes to the development of comor bidities, how it would do so is not clear. One speculative possibility is that uric acid contributes to gout comorbid ities through its effects as a DAMP. Both atherosclerosis and metabolic syndrome are now recognized to be sterile inflammatory diseases, and IL1 has been implicated in the pathogenesis of these conditions. 103, 104 Data also exist, albeit much more limited (that is, from only a few studies), implicating inflammation and IL1 in hyper tension. [105] [106] [107] Thus, these three comorbidities probably have an IL1 and inflammatory component. Moreover, the NLRP3 inflammasome-the same pathway of IL1 production that is triggered by MSU 59 -has been implicated in the pathogenesis of some comorbidities of gout (atherosclerosis 104 and metabolic syndrome 103 ), although it should be noted that the inflammasome is also triggered by other stimuli that can be associated with these comorbidities (such as cholesterol crystals in atherosclerosis 104 ). Moreover, in asymptomatic humans, an association has been observed between serum levels of uric acid and inflammatory markers. 108 Therefore, uric acid possibly contributes to the triggering of IL1 and inflammation locally or systemically, which then contributes to the development of comorbid conditions. However, it is also possible that uric acid might contri bute to comorbidities of gout in other ways, for instance by affecting redox potential, through direct effects on endothelium, 95, 96, 98 or by affecting lipid and/or cholesterol metabolism. 109 Further work is needed to understand the mechanisms underlying the relationships between uric acid and comorbidities of gout.
Implications for therapy
Presently, patients with gout are treated prophy lactically with agents that reduce serum levels of uric acid by inhibit ing its synthesis (xanthine oxidase inhibitors) or by increasing its excretion (uricosurics). Acute attacks of gout are treated with conventional antiinflammatory agents (such as NSAIDS) or colchicine. These agents are reasonably effective in treating this disease; however, not all patients tolerate or respond to treatment. Moreover, patients with gout, even when asymptomatic, can continue to have subclinical, smoldering inflammation, the treat ment of which might prevent joint erosion. 110, 111 For most other crystalbased or particlebased diseases essentially no therapies are available to prevent or arrest disease.
The elucidation of the mechanisms by which urate and other particles cause disease is important not only for understanding disease pathogenesis, but also for identi fying potential new targets for therapy. One such target is the cytokine IL1 and its receptor, IL1R1. A number of biologic agents that block IL1 pathways are approved for use in a number of indications, including rheumatoid arthritis and autoinflammatory diseases. These agents include a soluble IL1 receptor antagonist (anakinra), a recombinant IL1 receptor (IL1 Trap; rilonacept) and an antiIL1β monoclonal antibody (canakinumab), and more agents are under development. 38, 41 Anakinra has been tested in a very small number of patients with gout and was found to rapidly ameliorate symptoms. 112 Similarly, canakinumab and rilonacept have shown efficacy in treating gout. [113] [114] [115] [116] IL1blocking agents are currently being tested in the treatment of some of the comorbidities associated with gout, including diabetes mellitus and cardiovascular disease, and whether they are efficacious in other comorbidities as well as other sterile inflammatory diseases will be of interest to test. 38 AntiIL1 biologic agents have some potential limita tions. They are expensive, require injection and might confer an increased risk of infection. Therefore, the development of orally available smallmolecule inhibi tors of IL1, as well as inhibitors more selective for sterile inflammation, would be of interest. The identification of the molecular mechanisms of inflammasomedependent and independent pathways presents a number of poten tial drug targets, including the inflammasome itself and cathepsins.
As discussed above, uric acid is one of the DAMPs that is released by dying cells and stimulates inflam mation. This celldeathinduced inflammation can cause further tissue injury and contribute to disease, for example infarcts or other injuries. Depleting uric acid levels in animals reduces this kind of inflamma tion and, therefore, drugs that lower uric acid (such as xanthine oxidase inhibitors) could be used to suppress these responses. Whether this lowering of serum uric acid to very low levels would increase the suscepti bility of the host to infection or impair tumour immune sur veillance is unknown, although such problems have not been apparent in patients with gout who are treated with these agents.
Conclusions
Uric acid becomes immunostimulatory when it under goes a phase change by nucleating into crystals of MSU. This process occurs spontaneously in patients with hyperuricaemia who have supersaturating levels of uric acid in their biological fluids, and might occur locally when cells die and release their intracellular stores of uric acid. Upon its release from dying cells, uric acid is believed to be one of the DAMPs that alert the immune system to injurious situations. In response to DAMPs, the immune system generates, among other responses, an inflammatory response that mobilizes innate soluble and cellular defenses in an attempt to deal with the injury. Therefore, gout is possibly a consequence of inappropriate generation of a physiological signal that leads to inflammation and disease. The innate immune responses that are triggered by urate crystals could theo retically contribute to comorbidities of gout, although this concept is speculative. Urate crystals cause inflam mation by stimulating leukocytes to produce the pro inflammatory cytokine IL1β. This IL1 production occurs when the MSU particles are ingested by phago cytes, wherein they stimulate NLRP3 inflammasomes to activate the protease caspase1; the activated caspase1 then cleaves IL1β into its active form. In addition, MSU crystals stimulate cathepsin Cdependent proteases to generate bioactive IL1β. The inflammasome dependent and independent pathways of IL1 production are simi larly triggered by other irritant particles that cause disease. Therefore, common pathways exist through which many unrelated particles cause inflammation and disease. Recognition of these mechanisms could iden tify new molecular targets for therapeutics to potentially treat gout or other crystalbased diseases.
Review criteria
The PubMed database was searched for relevant literature using the following keywords, alone or in combination: "gout", "uric acid", "MSU", "monosodium urate", "comorbidity", "inflammasome", "DAMP", "danger signal", "irritant particles", "IL-1", "NLRP3", "ROS" and "macrophages". We focused primarily, but not exclusively, on publications since 2000 and English-language papers. The reference lists of the identified papers were screened for additional publications of relevance.
